Clinical guidelines are a powerful method for standardization and uniform improvement of the quality of medical care. In the proposed research project, which we call Asgaard, we will design and implement software solutions that support the design, application, and, in particular, quality assessment of the application of clinical guidelines by care providers. Our long- term objectives include provision of a standardized computational framework for specification, application, and runtime as well as retrospective quality assessment of clinical-guidelines. We will provide these solutions by using a novel framework for specification and interpretation of clinical guidelines. The new framework encodes explicitly both the therapeutic actions indicated by the guideline and the intermediate clinical process and outcome goals of the guideline designers, which we refer to as intentions. Intentions are represented as temporal patterns of care-provider actions or patient states to be maintained, achieved or avoided, using results from our previous work on interpretation and summarization of time-oriented clinical data. Intentions include both the intermediate and overall process pattern (care provider actions) to follow and the expected intermediate and final outcome pattern (patient states). The tasks that we are focusing on include (1) design-time tasks, such as specification, validation, and verification of the guideline, and (2) runtime tasks such as automated support to application of the guideline, recognition of care providers' intentions from their actions, and real-time as well as retrospective critiquing and quality assessment of care providers' application of he guideline, given the guideline and its intentions, the patient's medical record, and the analysis of the care provider's perceived intentions. In our previous work, we have designed a formal, machine- interpretable language, called Asbru, to represent and to annotate guidelines based on our framework, and implemented a small prototype interpreter for it. We will implement a full interpreter for the Asbru language and a set of software tools for specification, validation, and verification of Asbru guidelines. We will also design and implement a set of computational methods for runtime (during application) and retrospective quality assessment of clinical guideline application, both for individual patients and for populations of patients, using our intention-based model. We will rigorously test, validate, and evaluate our methodologies using collaborators in clinical areas such as oncology, immunology, and care of diabetes patients, and by launching a small pilot study and a large-scale evaluation using patient records from the Veterans Affairs Palo Alto Health Care System. We will transfer our technology to industry through ongoing collaborations with commercial enterprises.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA033049-21
Application #
6718490
Study Section
Subcommittee G - Education (NCI)
Program Officer
Xie, Heng
Project Start
1982-07-01
Project End
2005-09-15
Budget Start
2004-01-17
Budget End
2005-09-15
Support Year
21
Fiscal Year
2004
Total Cost
$1,889,948
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
McDevitt, Michael R; Thorek, Daniel L J; Hashimoto, Takeshi et al. (2018) Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. Nat Commun 9:1629
Casey, E; Bournazos, S; Mo, G et al. (2018) A new mouse expressing human Fc? receptors to better predict therapeutic efficacy of human anti-cancer antibodies. Leukemia 32:547-549
Budhu, Sadna; Schaer, David A; Li, Yongbiao et al. (2017) Blockade of surface-bound TGF-? on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci Signal 10:
Alidori, Simone; Thorek, Daniel L J; Beattie, Bradley J et al. (2017) Carbon nanotubes exhibit fibrillar pharmacology in primates. PLoS One 12:e0183902
Scheinberg, David A; Grimm, Jan; Heller, Daniel A et al. (2017) Advances in the clinical translation of nanotechnology. Curr Opin Biotechnol 46:66-73
Weber, Daniela; Jenq, Robert R; Peled, Jonathan U et al. (2017) Microbiota Disruption Induced by Early Use of Broad-Spectrum Antibiotics Is an Independent Risk Factor of Outcome after Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 23:845-852
Mathias, M D; Sockolosky, J T; Chang, A Y et al. (2017) CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes. Leukemia 31:2254-2257
Chang, Aaron Y; Gejman, Ron S; Brea, Elliott J et al. (2016) Opportunities and challenges for TCR mimic antibodies in cancer therapy. Expert Opin Biol Ther 16:979-87
Alidori, Simone; Akhavein, Nima; Thorek, Daniel L J et al. (2016) Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury. Sci Transl Med 8:331ra39
Alidori, Simone; Bowman, Robert L; Yarilin, Dmitry et al. (2016) Deconvoluting hepatic processing of carbon nanotubes. Nat Commun 7:12343

Showing the most recent 10 out of 289 publications